CompletedNCT00401973

Medicines to prevent weight gain from olanzapine

About this title

Medication studyAges 18–65Multiple countriesSchizophrenia

The study in practice

Understand this study

Listed age limits: 18 years to 65 years.

Listed locations: National City and 14 more locationsSee all locations and recruitment
Study phase: Phase 3

Study clarity

Study start dateNovember 2006

Recruitment status: Completed
Enrollment listed in the registry: 199
Sponsor: Eli Lilly and Company
Sponsor type: Other organization
Study type: Drug
Intervention type: Psychotherapy / behavioral intervention, Medication / drug
Study phase: Phase 3
Locations: United States, Brazil, Israel, ...
Age range: From 18 Years to 65 Years
Official registry ID: NCT00401973
Official title: Show the full official title
The Assessment of the Safety, Efficacy, and Practicality of an Algorithm Including Amantadine, Metformin and Zonisamide for the Prevention of Olanzapine-Associated Weight Gain in Outpatients With Schizophrenia

Completed

National City, United States · Canton, United States · Johnson City, United States

12 more locations

FAQ

Who is behind this study?

The study sponsor is Eli Lilly and Company.

Did this study involve medication?

Yes. The study involved medication, including olanzapine, amantadine, metformin and zonisamide.

Who was this study for?

Listed age limits: 18 years to 65 years.